26 commercial payer policies list J2327. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
26 policies from 17 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J2327 |
|---|---|---|
| Skyrizi (risankizumab-rzaa)Effective 05/01/2023 - 05/31/2024 | May 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Skyrizi Intravenous (risankizumab-rzaa) | Dec 1, 2025 | Prior auth requiredInferred from policy title |
| Skyrizi Intravenous (risankizumab-rzaa)Effective 06/01/2024 - 11/30/2024 | Jun 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Skyrizi Intravenous (risankizumab-rzaa)Effective 12/01/2024 - 11/30/2025 | Dec 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J2327 |
|---|---|---|
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Skyrizi (Risankizumab-Rzaa) | Aug 1, 2026 | Covered |
| Skyrizi (Risankizumab-Rzaa) – Commercial and Individual Exchange Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Skyrizi (Risankizumab-Rzaa) – Community Plan Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Risankizumab-rzaa (Skyrizi) for intravenous use | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Risankizumab-rzaa (Skyrizi) for Intravenous Use | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Risankizumab-rzaa (Skyrizi) for intravenous use | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Risankizumab-rzaa (Skyrizi) for Intravenous Use | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Skyrizi (Risankizumab-Rzaa) | Aug 1, 2026 | Covered |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Risankizumab (e.g., Skyrizi) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Risankizumab-rzaa | May 15, 2026 | Covered |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Risankizumab-rzaa | May 15, 2026 | Covered |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Risankizumab-rzaa | May 15, 2026 | Covered |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Risankizumab-rzaa | May 15, 2026 | Covered |
| Policy | Effective | Status of J2327 |
|---|---|---|
| SKYRIZI IV (RISANKIZUMAB-RZAA) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Risankizumab-rzaa (Skyrizi) | Sep 30, 2022 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Skyrizi IV Criteria | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2327 |
|---|---|---|
| 00677 risankizumab-rzaa (Skyrizi) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Skyrizi (risankizumab-rzaa) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Skyrizi (risankizumab-rzaa) Subcutaneous | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2327 |
|---|---|---|
| Skyrizi (Risankizumab-Rzaa) | Aug 1, 2026 | Covered |